Good 5-Year Durability of Transapical Beating Heart Off-Pump Mitral Valve Repair With Neochordae
Kiefer and colleagues report the outcomes of six patients who underwent transapical mitral valve repair for severe mitral regurgitation. Treatment was offered as part of the safety and feasibility trial for the NeoChord DS1000 system at the authors’ institution. One patient underwent intraoperative conversion to an open repair, two patients underwent reoperation for recurrent mitral regurgitation, and the remaining three patients had no cardiac symptoms throughout the five-year follow-up period.
Small case series that has to be read in the wider context of https://www.ctsnet.org/jans/percutaneous-repair-or-medical-treatment-secondary-mitral-regurgitation#comment-2326
As exciting as this new technology is, the title “Good 5-Year Durability…” does not accurately reflect the results with a 50% failure rate (one conversion and two reoperations). It’s very misleading. When considering the idea that this would be used in otherwise reasonable surgical candidates this report should yield some concern and we certainly need much more data before we consider such therapies in all but the highest risk patients.
Hear Hear…